Raphael Pharmaceutical Inc.
RAPH
Rank in Stocks
#24778
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating... Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Share Price
$1.51
Last synced: 2026-11-10
Market Cap
$30.47M
Change (1 day)
0.00%
Change (1 year)
51.00%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Raphael Pharmaceutical Inc. (RAPH)
Category
Healthcare
P/E ratio for Raphael Pharmaceutical Inc. (RAPH)
P/E ratio as of November 2026 TTM: -30.69
According to Raphael Pharmaceutical Inc.'s latest financial reports and stock price, its current price-to-earnings ratio (TTM) is -30.69. At the end of 2025 the company had a P/E ratio of -21.41.
P/E ratio history for Raphael Pharmaceutical Inc. from 2021 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -30.69 | 43.35% |
| 2025 | -21.41 | 569.71% |
| 2024 | -3.20 | -74.30% |
| 2023 | -12.44 | 32.38% |
| 2022 | -9.40 | -55.21% |
| 2021 | -20.98 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 23.34 | -176.04% |
DE
|
|
| 27.76 | -190.45% |
DE
|
|
| 27.16 | -188.51% |
JP
|
|
| 63.88 | -308.13% |
CH
|
|
| 64.74 | -310.95% |
IL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.
Questions about Raphael Pharmaceutical Inc.'s P/E ratio
What is Raphael Pharmaceutical Inc.'s P/E ratio?
Raphael Pharmaceutical Inc.'s P/E ratio is -30.69, as of Nov 2026.
What was Raphael Pharmaceutical Inc.'s P/E ratio in 2025?
In 2025, Raphael Pharmaceutical Inc.'s P/E ratio was -21.41, compared with -3.20 in 2024.
How has Raphael Pharmaceutical Inc.'s P/E ratio changed since 2021?
From 2021 to 2025, Raphael Pharmaceutical Inc.'s P/E ratio was highest in 2024 (-3.20) and lowest in 2025 (-21.41).
How does Raphael Pharmaceutical Inc.'s P/E ratio compare with similar companies?
Raphael Pharmaceutical Inc.'s P/E ratio (-30.69) is lower than that of all 5 similar companies listed above. The highest among them is Teva Pharmaceutical Industries Limited, with 64.74.